Medical staff examine a patient in the Covid-19 intensive care unit at the United Memorial Medical Center in Houston on November 16, 2020.
Go Nakamura | Getty Images
LONDON – Swiss biotech company Relief Therapeutics has seen its share price rise 38,000 per cent so far this year as it develops a drug focused on respiratory failure arising from severe Covid-19.
Last week, the company, in partnership with U.S. partner NeuroRX, launched a U.S. In their ongoing Phase 2B / 3 trial of RLF-100 with the Food and Drug Administration reached the enrollment target of 165 patients, the patented version of Avipatdil.
Aviptadil is a synthetic formulation of a naturally occurring peptide called vasoactive intestinal polypeptide (VIP), which is primarily concentrated in the lungs and serves as a vasodilator and works to reset the immune response by increasing the production of surfactant in the lungs. Enables transfer.
The RLF-100 dates to around 2000, when it was developed to treat acute respiratory distress and other lung conditions and was subsequently acquired by Biogen. Earlier this year, relief scientists discovered that it could protect cells attacked by the Cell-19 virus.
Speaking to CNBC by telephone from New York, Relief Healing Chairman Ram Selvaraju said the ongoing trial is expected to provide topline data in early January, and is attributed to the weather rise in the company’s share price based on evidence of its effectiveness. “Patients who cannot be treated otherwise.”
“Where others have focused primarily on mildly infected or moderately infected people, we have quickly and sincerely tried to see if our medication is seriously ill and can benefit those in the final stages.”
The results of the initial phase of extended use of RLF-100 in patients with critical covid-19 and severe comorbidities showed 72% of those living in the ICU.
Relief Therapeutics had a market cap of less than 100 million Swiss francs (11 113 million) at the end of July, and surpassed that on August 10 after the promising results of 21 patients before being treated with RLF-100 under FDA extended access protocol authorization. 1.6 billion Swiss. Since then it has been flattened under just 1 billion Swiss francs.
The figure of 38,000% represents a small part of the initial share price, which was just below 0.40 Swiss francs per share as of noon on Friday. In contrast, shares of the multinational Roche are worth 306 Swiss francs.
More therapeutic symptoms on patients are being purchased by government agencies seeking to fight other therapeutic epidemics, U.S. The government’s operational speed has been ordered by Remedesivir of Gilead and Bamlanivimab of Eli Lilly.
Selvaraju revealed that Relief Therapeutics and NeuroRX were in touch with the operation and Speed Speed and said that if the drug successfully proves its effectiveness after a three-stage randomized trial in critically ill patients, the company will keep stockpiling on the same basis of Gilead’s choice. And Ally Lily. CNBC A spokesman for the U.S. Department of Health and Human Services was not immediately available for comment.
‘Iceberg top’ covid
In June, the FDA gave the RLF-100 a fast-track designation, and an orphan drug designation for the treatment of Acute Respiratory Distress Syndrome (ARDS).
The drug is not a specially formulated antiviral to combat coronavirus, so Relief Therapeutics hopes that the current epidemic is an “opportunity to shine this drug” if the therapeutic clinical utility in eliminating covid-induced respiratory complications is proven. 19.
“Covid-1 is really the tip of the iceberg, the head of the spear. If we prove that this drug works in Covid-19 related respiratory distress, we assume that we will be able to pass those results on in drug testing,” Selvaraju said. That, among other forms of acute respiratory distress syndrome that has nothing to do with Covid-19, “he added, puts this relief therapy in a” pretty unique state. “
“While many other experimental therapies live or die depending on how the epidemic develops, we feel the opposite. Once we establish the therapeutic utility of this drug in the context of Covid-19, hopefully, our long-term vision will be in the emergency room. And for intensive care units and hospitals and hospital systems, this drug becomes a kind of workaholic drug. “
.
